Update 62-1 Idelalisib: A First-in-Class Specific Inhibitor of PI3Kδ for the Treatment of B-cell lymphomas (ABSTRACT)


The FDA granted idelalisib (Zydelig) accelerated approval  in July 2014 for treatment of relapsed follicular B cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL).  Idelalisib is a first-in-class oral inhibitor of the enzyme phosphatidyl-inositol 3 kinase-d (PI3Kδ) isoform. The PI3Kδ isoform in the PI3K signaling pathway is constitutively activated in many B-cell malignancies and inhibition of this pathway promotes apoptosis in these cancerous cells. (CLICK FOR eUPDATE 62-1 IN eSECTION VIII IN TOC)